ライフサイエンスコーパス: renalase

1 tumor mass, suggesting a pathogenic role for renalase.

2 mmon single nucleotide polymorphism in human renalase 3'-UTR (C/T; rs10749571) creates a binding site

3 -29a/b/c and miR-146a/b with mouse and human renalase 3'-UTR (untranslated region) in cultured cells.

4 consistently, miR-146a down-regulated human renalase 3'-UTR/luciferase activity in case of the T all

5 Renalase, a recently discovered secreted flavoprotein, p

6 Renalase, a recently identified oxidoreductase, is emerg

7 We previously identified renalase, a secreted novel amine oxidase that specifical

8 of immunohistochemistry was used to localize renalase across time course from 17 weeks to term.

9 rge of epinephrine lasting <2 minutes causes renalase activity to increase from 48+/-18 to 2246+/-98

10 Renalase, an amine oxidase secreted by the proximal tubu

11 nohistochemistry, and immunofluorescence for renalase and its binding partners, PMCA4b and PZP, were

12 Renalase and its receptor PMCA4b transcripts and protein

13 ase signaling using siRNA or inhibitory anti-renalase antibodies decreased the viability of cultured

14 We have identified the catalytic activity of renalase as an alpha-NAD(P)H oxidase/anomerase, whereby

15 These results identify renalase as what we believe to be a novel amine oxidase

16 Inhibition of renalase caused tumor cell apoptosis and cell cycle arre

17 also leads to a 2.8-fold increase in plasma renalase concentration.

18 It is not known whether endogenous renalase contributes to the regulation of catecholamines

19 d plasma catecholamine levels were higher in renalase-deficient mice subjected to renal ischemia repe

20 erall survival was inversely correlated with renalase expression in the tumor mass, suggesting a path

21 Here we show that renalase expression is increased in pancreatic cancer ti

22 e estimated miR-29b and miR-146a, as well as renalase expression, in genetically hypertensive blood p

23 terleukin-2 (IL-2), IL2/4q27 (rs2069763) and renalase, FAD-dependent amine oxidase (RNLS)/10q23.31 (r

24 DPH and NADH initiate rapid reduction of the renalase flavin cofactor.

25 dence for post-transcriptional regulation of renalase gene by miR-29 and miR-146 and has implications

26 exposed to dopamine upregulate steady-state renalase gene expression by >10-fold.

27 In humans, renalase gene expression is highest in the kidney but is

28 possible role of microRNAs in regulation of renalase gene in this study.

29 The mechanism of regulation of renalase gene, especially at the post-transcriptional le

30 Since its discovery in 2005, renalase has been the subject of conjecture pertaining t

31 However, placental villi contained more renalase immunoreactive cells in fetal than full-term pl

32 eveal a previously unrecognized role for the renalase in cancer: its expression may serve as a progno

33 ggesting its potential role in regulation of renalase in humans.

34 rophoblasts, suggesting a potential role for renalase in placental development and function.

35 We examined the potential role of renalase in placental development.

36 ion injury had significantly lower levels of renalase in the plasma and kidney compared with sham-ope

37 Renalase infusion in rats caused a decrease in cardiac c

38 onal antibody m28-RNLS or shRNA knockdown of renalase inhibited pancreatic ductal adenocarcinoma grow

39 Renalase is a flavoprotein whose structural topology is

40 Renalase is a pro-survival, anti-inflammatory flavoprote

41 Renalase is a protein hormone secreted into the blood by

42 Renalase is endogenously expressed throughout placental

43 The plasma concentration of renalase is markedly reduced in patients with end-stage

44 While it has been widely reported that renalase is the third monoamine oxidase (monoamine oxida

45 We show here that circulating renalase lacks significant amine oxidase activity under

46 ministration of either native or recombinant renalase lowers blood pressure, heart rate, and cardiac

47 ney and metabolizes catecholamines in vitro (renalase metabolizes dopamine most efficiently, followed

48 apoptosis, and inflammation, and that plasma renalase might be a biomarker for AKI.

49 In two xenograft mouse models, either the renalase monoclonal antibody m28-RNLS or shRNA knockdown

50 h mice showed diminished (~1.6- to 1.8-fold) renalase mRNA/protein levels and elevated (~2.2-fold) mi

51 In the renalase pathway, excess catecholamine facilitates the c

52 Renalase plasma levels are markedly reduced in patients

53 Taken together, these data suggest that renalase protects against ischemic AKI by reducing renal

54 Administration of recombinant human renalase reduced plasma catecholamine levels and amelior

55 vels, cardiac hypertrophy, and hypertension, renalase replacement is an attractive therapeutic modali

56 ed that the kidney-secreted survival protein renalase (RNLS) and an agonist peptide protected mice fr

57 We previously identified Renalase (Rnls) as a novel target for beta-cell protecti

58 Protective Renalase (Rnls) deficiency impacts beta-cell metabolism.

59 Renalase (RNLS) is a secreted flavoprotein that function

60 Renalase (RNLS) is an anti-inflammatory secretory flavop

61 1390 located to a region 58.8 kb upstream of renalase (RNLS) with eGFR was detected in the Ludwigshaf

62 Future studies should assess renalase's role in normal and diseased human placenta.

63 Inhibition of renalase signaling using siRNA or inhibitory anti-renala

64 denine dinucleotide-dependent amine oxidase (renalase) that is secreted into the blood by the kidney

65 Recombinant renalase therapy may have potential for the prevention a

66 Endogenous production of renalase was examined in placental tissue and organoids.

67 nalase, an inactive plasma amine oxidase, to renalase, which can degrade catecholamines.